Minimed Group, INC

MiniMed Group, Inc. announced the successful completion of its exchange offer, separating from Medtronic plc and commencing operations as a fully independent company.

MiniMed Group, Inc. announced a robust start to fiscal year 2027, with net sales reaching $843 million, a 17% increase driven by accelerated U.S. growth and strong international performance.

MiniMed Group, Inc. reports the resignation of its Senior Vice President, General Counsel, and Corporate Secretary, Courtney Nelson Wills, effective September 25, 2026.

MiniMed Group, Inc. announced an expansion of its Board of Directors with two new appointments and set the date and record date for its 2026 Annual Meeting of Stockholders.

MiniMed announced record fiscal year 2026 net sales exceeding $3 billion, with Q4 sales up 15.6% year-over-year, driven by international markets and new product clearances.

MiniMed Group, Inc. reports the resignation of director Brett Wall and the appointment of Scott Cundy to the Board of Directors.

MiniMed Group, Inc. announced a 16.6% increase in net sales for the first quarter of fiscal year 2027, driven by robust performance in CGM and pump segments, alongside strategic product advancements.

MiniMed Group reports Q3 2026 net sales of $790 million, reflecting a 15% increase, alongside a net loss of $111 million driven by restructuring and litigation charges.

MiniMed Group, Inc. announced its fiscal year 2026 results, showcasing a 14% increase in net sales to $3.1 billion, primarily fueled by robust international growth in its CGM segment.

Timothy A Wicks, a Director of MiniMed Group, Inc., received 11,795 shares of common stock on October 9, 2026.

Kevin E Lofton, a Director of MiniMed Group, Inc., received 11,795 shares of common stock on October 9, 2026.

D Keith Grossman, a Director of MiniMed Group, Inc., received 11,795 shares of common stock on October 9, 2026.

David J. Endicott, a Director of MiniMed Group, Inc., received 11,795 shares of common stock on October 9, 2026.

Glenn A Eisenberg, a Director of MiniMed Group, Inc., received 11,795 shares of common stock on October 9, 2026.

Sheila A. Denton, SVP, Gen. Counsel & Corp. Sec. of MiniMed Group, Inc., received 58,939 shares of common stock on October 1, 2026.

MiniMed Group, Inc. has announced its 2026 Annual Meeting of Stockholders, detailing key proposals including director elections, auditor ratification, and executive compensation votes.

MiniMed Group, a global leader in diabetes technology, filed an S-1/A for its initial public offering of 28 million shares, showcasing robust revenue growth and product innovation despite reporting significant net losses and operational challenges.

MiniMed Group, Inc., a global medical technology company specializing in diabetes management, filed an amended S-1 registration statement detailing its initial public offering of 28 million shares and its spin-off from Medtronic, aiming to accelerate growth as an independent entity.

Medtronic plc has filed a Schedule 13G reporting beneficial ownership of 90% of the outstanding common stock of MiniMed Group, Inc.